Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +75

MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion

AI-generated analysis

📈 MiniMed shares rose 7% to $13.14 in pre-market trading following positive financial results and partnership news.

💰 The company reported $837 million in fiscal fourth-quarter sales, exceeding analyst expectations of $827.9 million.

🌍 Revenue growth was primarily driven by a 22% increase in international sales figures.

🤝 MiniMed expanded its strategic agreement with Abbott Laboratories to commercialize new glucose-ketone sensors.

🔬 The new sensors are designed to integrate exclusively with MiniMed's smart dosing systems for diabetes management.

🔄 This partnership builds on the existing collaboration for the Instinct sensor manufactured by Abbott.

🩸 The expanded choice of sensors will benefit users across automated insulin delivery and Smart MDI systems.

Bullish Signals
  • MiniMed shares rose 7% to $13.14 in pre-market trading following the release of strong fourth-quarter results.
  • The company posted $837 million in fiscal fourth quarter sales, beating analyst estimates of $827.9 million by nearly $10 million.
  • Revenue growth was significantly driven by a 22% increase in international sales, highlighting global demand for diabetes management technology.
  • MiniMed expanded its strategic partnership with Abbott Laboratories to commercialize new glucose-ketone sensors designed exclusively for MiniMed's smart dosing systems.
  • The enhanced agreement will bring expanded choice to users across automated insulin delivery and Smart MDI systems, strengthening the company's product ecosystem.
Risk Factors
  • MiniMed shares rose 7% to $13.14 in pre-market trading, indicating positive market sentiment rather than negative risk.
Full Analysis
MiniMed shares increased by 7% to $13.14 in pre-market trading following the release of fourth-quarter financial results that exceeded analyst expectations. The company reported revenue of $837 million for the fiscal quarter, surpassing the consensus estimate of $827.9 million provided by FactSet. This growth was primarily driven by a 22% increase in international sales, indicating strong demand outside its domestic market. In addition to the financial performance, MiniMed announced an expansion of its strategic partnership with Abbott Laboratories. The new agreement focuses on commercializing glucose-ketone sensors that will integrate exclusively with MiniMed's smart dosing systems. This development builds upon the companies' existing collaboration regarding the Instinct sensor and is expected to provide users with expanded options for automated insulin delivery and Smart MDI systems, enhancing the overall ecosystem for diabetes management technology.